Nppb (natriuretic peptide B) - Rat Genome Database

Send us a Message



Rat Genome Database
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Grant Resources Citing RGD About Us Contact Us
Search by Genomic Position Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quantitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Behavioral & Substance Use Disorder Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)
Gene: Nppb (natriuretic peptide B) Rattus norvegicus
Analyze
Symbol: Nppb
Name: natriuretic peptide B
RGD ID: 3194
Description: Predicted to enable hormone activity and hormone receptor binding activity. Involved in several processes, including cellular response to mechanical stimulus; negative regulation of cell population proliferation; and positive regulation of collecting lymphatic vessel constriction. Located in extracellular region and perinuclear region of cytoplasm. Used to study hypertension; hypertensive heart disease; myocardial infarction; polycystic kidney disease; and proteinuria. Biomarker of several diseases, including artery disease (multiple); heart disease (multiple); hyperhomocysteinemia; obesity; and type 2 diabetes mellitus. Human ortholog(s) of this gene implicated in atherosclerosis; hypertension; myocardial infarction; obesity; and systolic heart failure. Orthologous to human NPPB (natriuretic peptide B); PARTICIPATES IN brain natriuretic peptide signaling pathway; INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine; 3,3',4,4',5-pentachlorobiphenyl.
Type: protein-coding
RefSeq Status: PROVISIONAL
Previously known as: Bnf; BNP; Brain natriuretic factor; brain natriuretic factor prohormone; brain natriuretic peptide; gamma-brain natriuretic peptide; iso-ANP; natriuretic peptide precursor B; natriuretic peptide precursor type B; natriuretic peptides B; preproBNP; proBNP
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Black Rat
Alliance Orthologs
More Info more info ...
Allele / Splice: Nppbem2Mcwi ; Nppbem4Mcwi
Genetic Models: SS-Nppbem4Mcwi ; SS-Nppbem2Mcwi-/- ; SS-Nppbem2Mcwi
Is Marker For: Strains:   SD
QTLs:   Bp100  
Candidate Gene For: Bp155
Latest Assembly: GRCr8 - GRCr8 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr85163,699,955 - 163,701,314 (+)NCBIGRCr8GRCr8GRCr8
GRCr8 Ensembl5163,699,839 - 163,701,310 (+)EnsemblGRCr8
mRatBN7.25158,416,813 - 158,418,175 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl5158,416,866 - 158,418,168 (+)EnsemblmRatBN7.2
UTH_Rnor_SHR_Utx5161,133,613 - 161,134,915 (+)NCBIUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.05162,961,436 - 162,962,738 (+)NCBIUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.05162,917,783 - 162,919,085 (+)NCBIUTH_Rnor_WKY_Bbb_1.0
Dahl_SR_JrHsd5163,279,648 - 163,280,950 (+)NCBI
Lyon_Normotensive5165,292,669 - 165,293,971 (+)NCBI
Lyon_Hypertensive5164,468,266 - 164,469,568 (+)NCBI
F344_StmMcwi5158,012,664 - 158,013,966 (+)NCBI
Rnor_6.05164,796,176 - 164,797,538 (+)NCBIRnor_6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl5164,796,185 - 164,797,531 (+)EnsemblRnor_6.0 Ensemblrn6Rnor6.0
Rnor_5.05168,454,278 - 168,455,640 (+)NCBIRnor_5.0Rnor_5.0rn5
RGSC_v3.45165,062,348 - 165,063,650 (+)NCBIRGSC_v3.4RGSC_v3.4rn4
Celera5156,698,873 - 156,700,175 (+)NCBICelera
RGSC_v3.15165,072,535 - 165,073,838 (+)NCBI
Cytogenetic Map5q36NCBI
JBrowse:




Disease Annotations     Click to see Annotation Detail View
acute kidney failure  (IEP,ISO)
adult respiratory distress syndrome  (ISO)
Animal Disease Models  (ISO)
anti-basement membrane glomerulonephritis  (ISO)
aortic valve insufficiency  (ISO)
atherosclerosis  (ISO)
atrial fibrillation  (ISO)
Brain Injuries  (ISO)
Cardiomegaly  (IDA,IEP,ISO)
cardiomyopathy  (ISO)
Cardiotoxicity  (ISO)
cardiovascular system disease  (ISO)
Cerebral Hemorrhage  (ISO)
chronic kidney disease  (ISO)
congenital heart disease  (ISO)
congestive heart failure  (IEP,ISO)
Contrast-Induced Nephropathy  (ISO)
coronary artery disease  (ISO)
COVID-19  (ISO)
Death  (ISO)
diabetes mellitus  (ISO)
Diabetic Nephropathies  (ISO)
dilated cardiomyopathy  (ISO)
Dyspnea  (ISO)
Eisenmenger Complex  (ISO)
end stage renal disease  (ISO)
essential hypertension  (ISO)
Experimental Diabetes Mellitus  (IEP)
heart disease  (IEP,ISO)
High Cardiac Output  (ISO)
hyperhomocysteinemia  (IEP)
hypertension  (IDA,IEP,ISO)
hypertensive heart disease  (IDA)
Hypertensive Nephropathy  (IMP)
hypertrophic cardiomyopathy  (IEP)
hypokalemia  (ISO)
Hyponatremia  (ISO)
Hypotension  (ISO)
Inflammation  (ISO)
Insulin Resistance  (ISO)
Kawasaki disease  (ISO)
left ventricular failure  (IEP,ISO)
Left Ventricular Hypertrophy  (IDA,IEP,ISO)
liver cirrhosis  (ISO)
Metabolic Side Effects of Drugs and Substances  (IEP)
migraine  (ISO)
morbid obesity  (ISO)
myocardial infarction  (IEP,IMP,ISO)
Myocardial Reperfusion Injury  (IDA)
nephrosis  (IEP)
obesity  (IEP,ISO)
Pain  (ISO)
polycystic kidney disease  (IDA)
Postoperative Complications  (ISO)
proteinuria  (IMP)
pulmonary embolism  (ISO)
pulmonary hypertension  (IEP,ISO)
renal hypertension  (IEP,ISO)
sickle cell anemia  (ISO)
systolic heart failure  (ISO)
type 2 diabetes mellitus  (IEP,ISO)
ureteral obstruction  (ISO)
Vasovagal Syncope  (ISO)
Ventricular Dysfunction, Right  (ISO)
Ventricular Remodeling  (ISO)
Ventricular Tachycardia  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(5Z,8Z,11Z,13E)-15-HETE  (ISO)
(R)-noradrenaline  (ISO)
1,10-phenanthroline  (ISO)
1,2-dimethylhydrazine  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2-(3,4-dimethoxyphenyl)-5-\{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino\}-2-(propan-2-yl)pentanenitrile  (ISO)
3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine  (EXP)
3,3',4,4',5-pentachlorobiphenyl  (EXP)
3,3',5'-triiodo-L-thyronine  (EXP)
3,5-diethoxycarbonyl-1,4-dihydrocollidine  (ISO)
3-[3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1,1-diethylurea  (ISO)
3-methyladenine  (EXP)
3-methylcholanthrene  (EXP)
4,4'-diaminodiphenylmethane  (EXP)
4,4'-sulfonyldiphenol  (ISO)
5-azacytidine  (ISO)
6-propyl-2-thiouracil  (EXP)
acetylsalicylic acid  (EXP,ISO)
aflatoxin B1  (ISO)
aldehydo-D-glucose  (EXP)
aldosterone  (ISO)
all-trans-retinoic acid  (ISO)
aluminium phosphide  (EXP)
ammonium chloride  (EXP)
angiotensin II  (ISO)
anthra[1,9-cd]pyrazol-6(2H)-one  (ISO)
arecoline  (EXP)
arsane  (EXP)
arsenic atom  (EXP)
aspartame  (ISO)
atenolol  (EXP,ISO)
atorvastatin calcium  (ISO)
atrazine  (EXP)
bellidifolin  (EXP,ISO)
benazepril  (EXP)
benidipine  (ISO)
benzo[a]pyrene  (EXP,ISO)
beta-naphthoflavone  (EXP,ISO)
betaxolol  (EXP)
bis(2-ethylhexyl) phthalate  (ISO)
bisphenol A  (EXP,ISO)
bisphenol AF  (ISO)
bisphenol F  (ISO)
bosentan  (ISO)
butyric acid  (EXP)
cadmium atom  (EXP)
cadmium dichloride  (EXP,ISO)
caffeine  (EXP)
calcitriol  (EXP)
Candesartan cilexetil  (EXP)
captopril  (EXP)
carvedilol  (EXP,ISO)
chlorogenic acid  (EXP)
chlorpromazine  (EXP)
chromium atom  (ISO)
cisplatin  (ISO)
citronellal  (EXP)
cobalt dichloride  (ISO)
cobalt(2+) sulfate  (ISO)
copper atom  (ISO)
copper(0)  (ISO)
copper(II) sulfate  (ISO)
corilagin  (EXP)
crocidolite asbestos  (ISO)
crotonaldehyde  (EXP)
cucurbitacin I  (EXP)
cyclophosphamide  (ISO)
cyclosporin A  (EXP,ISO)
cytarabine  (ISO)
D-glucose  (EXP)
dantrolene  (EXP)
daunorubicin  (EXP,ISO)
decabromodiphenyl ether  (EXP)
dehydroepiandrosterone  (ISO)
dexamethasone  (ISO)
dibromine  (EXP)
diethylstilbestrol  (ISO)
digoxin  (ISO)
dinophysistoxin 1  (ISO)
dioxygen  (EXP,ISO)
dipyridamole  (ISO)
diquat  (ISO)
disulfiram  (ISO)
donepezil hydrochloride  (ISO)
dorsomorphin  (ISO)
doxazosin  (EXP,ISO)
doxorubicin  (EXP,ISO)
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor  (EXP,ISO)
ellagic acid  (EXP)
enalapril  (EXP)
endosulfan  (EXP)
ethanol  (EXP,ISO)
famotidine  (EXP)
fasudil  (ISO)
febuxostat  (EXP)
fenofibrate  (EXP)
fenthion  (EXP)
fenvalerate  (EXP)
folic acid  (ISO)
formaldehyde  (EXP)
fructose  (EXP)
fulvestrant  (ISO)
furan  (EXP)
gallic acid  (EXP)
gefitinib  (EXP)
gentamycin  (EXP)
glucose  (EXP)
glyburide  (EXP)
graphite  (EXP,ISO)
GW 501516  (EXP)
HET0016  (EXP)
hydralazine  (EXP)
hydrochlorothiazide  (EXP)
idarubicin  (ISO)
indole-3-acetic acid  (EXP)
indoxyl sulfate  (EXP,ISO)
isoprenaline  (EXP,ISO)
ivermectin  (ISO)
lead nitrate  (EXP)
linderalactone  (EXP,ISO)
lipopolysaccharide  (EXP,ISO)
lithium chloride  (EXP)
losartan  (EXP)
melatonin  (EXP)
melphalan  (ISO)
mercury dibromide  (ISO)
mercury dichloride  (ISO)
methamphetamine  (EXP)
methotrexate  (ISO)
methylmercury chloride  (ISO)
metoprolol  (EXP)
mirtazapine  (EXP,ISO)
mono(2-ethylhexyl) phthalate  (ISO)
monocrotaline  (EXP)
N(gamma)-nitro-L-arginine methyl ester  (EXP)
N-methyl-4-phenylpyridinium  (EXP)
nebivolol  (ISO)
neohesperidin  (EXP,ISO)
nickel sulfate  (ISO)
nifedipine  (EXP)
nitric oxide  (EXP)
nitrofen  (EXP)
nitroprusside  (ISO)
Olmesartan medoxomil  (EXP)
p-chloromercuribenzoic acid  (ISO)
paracetamol  (EXP)
Pedunculoside  (EXP)
Pentoxifylline  (ISO)
perfluorohexanesulfonic acid  (ISO)
perfluorononanoic acid  (ISO)
perfluorooctane-1-sulfonic acid  (EXP,ISO)
phenylephrine  (EXP,ISO)
phenylhydrazine  (EXP)
phenylmercury acetate  (ISO)
pioglitazone  (ISO)
pirarubicin  (EXP)
pirinixic acid  (EXP,ISO)
Plantamajoside  (EXP,ISO)
platycodin D  (EXP)
plumbagin  (EXP)
potassium chromate  (ISO)
pregabalin  (EXP)
progesterone  (EXP)
propranolol  (EXP)
prostaglandin E1  (ISO)
prostaglandin E2  (EXP)
pyrrolidine dithiocarbamate  (EXP)
quercetin  (EXP)
ramipril  (EXP)
resveratrol  (EXP,ISO)
rifampicin  (ISO)
robinin  (EXP)
rotenone  (ISO)
SB 203580  (EXP)
SB 431542  (ISO)
scutellarin  (ISO)
serpentine asbestos  (ISO)
sildenafil citrate  (EXP,ISO)
silicon dioxide  (ISO)
silver atom  (ISO)
silver(0)  (ISO)
simvastatin  (EXP)
sirolimus  (EXP)
sodium arsenite  (EXP,ISO)
spironolactone  (ISO)
streptozocin  (EXP,ISO)
sunitinib  (EXP,ISO)
tacrolimus hydrate  (ISO)
Tanshinone I  (ISO)
telmisartan  (EXP,ISO)
Temocapril hydrochloride  (ISO)
tert-butyl hydroperoxide  (ISO)
thalidomide  (ISO)
Theaflavin 3,3'-digallate  (EXP)
thiabendazole  (EXP)
thymoquinone  (EXP)
titanium dioxide  (ISO)
trichloroethene  (EXP)
trichostatin A  (ISO)
triclosan  (ISO)
triptonide  (ISO)
troglitazone  (EXP)
valproic acid  (ISO)
valsartan  (EXP,ISO)
verapamil  (ISO)
verteporfin  (EXP)
vitamin E  (EXP)
vorinostat  (ISO)
zinc atom  (ISO)
zinc(0)  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Cellular Component

Molecular Function

Molecular Pathway Annotations     Click to see Annotation Detail View
Phenotype Annotations     Click to see Annotation Detail View

Mammalian Phenotype
References

References - curated
# Reference Title Reference Citation
1. 3-methylcholanthrene and benzo(a)pyrene modulate cardiac cytochrome P450 gene expression and arachidonic acid metabolism in male Sprague Dawley rats. Aboutabl ME, etal., Br J Pharmacol. 2009 Dec;158(7):1808-19. doi: 10.1111/j.1476-5381.2009.00461.x.
2. Ultrastructural changes, increased oxidative stress, inflammation, and altered cardiac hypertrophic gene expressions in heart tissues of rats exposed to incense smoke. Al-Attas OS, etal., Environ Sci Pollut Res Int. 2015 Jul;22(13):10083-93. doi: 10.1007/s11356-015-4212-5. Epub 2015 Feb 18.
3. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Andreassen AK, etal., Am J Cardiol. 2006 Aug 15;98(4):525-9. Epub 2006 Jun 28.
4. Prognostic role of B-type natriuretic peptide in patients with diabetes and acute decompensated heart failure. Aspromonte N, etal., Diabet Med. 2007 Feb;24(2):124-30.
5. Log-transformed plasma level of brain natriuretic peptide during the acute phase of Kawasaki disease is quantitatively associated with myocardial dysfunction. Bang S, etal., Korean J Pediatr. 2011 Aug;54(8):340-4. Epub 2011 Aug 31.
6. Cardioprotective role of growth/differentiation factor 1 in post-infarction left ventricular remodelling and dysfunction. Bao MW, etal., J Pathol. 2015 Jul;236(3):360-72. doi: 10.1002/path.4523. Epub 2015 Mar 30.
7. Impact of the Look AHEAD Intervention on NT-pro Brain Natriuretic Peptide in Overweight and Obese Adults With Diabetes. Bertoni AG, etal., Obesity (Silver Spring). 2011 Sep 29. doi: 10.1038/oby.2011.296.
8. Impact of obesity on the expression profile of natriuretic Peptide system in a rat experimental model. Cabiati M, etal., PLoS One. 2013 Aug 29;8(8):e72959. doi: 10.1371/journal.pone.0072959.
9. Scar myofibroblasts of the infarcted rat heart express natriuretic peptides. Calderone A, etal., J Cell Physiol. 2006 Apr;207(1):165-73.
10. Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Cataliotti A, etal., Circulation. 2011 Mar 29;123(12):1297-305. Epub 2011 Mar 14.
11. Ventricular function and natriuretic peptides in sequentially combined models of hypertension. Cavallero S, etal., Am J Physiol Heart Circ Physiol. 2010 Apr;298(4):H1290-9. doi: 10.1152/ajpheart.00911.2009. Epub 2010 Feb 5.
12. Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. Chen HH, etal., J Am Coll Cardiol. 2012 Dec 4;60(22):2305-12. doi: 10.1016/j.jacc.2012.07.056. Epub 2012 Nov 1.
13. Increased natriuretic peptide receptor A and C gene expression in rats with pressure-overload cardiac hypertrophy. Christoffersen TE, etal., Am J Physiol Heart Circ Physiol. 2006 Apr;290(4):H1635-41. Epub 2005 Nov 4.
14. Differential expression of natriuretic peptide genes in cardiac and extracardiac tissues. Dagnino L, etal., Mol Endocrinol 1991 Sep;5(9):1292-300.
15. Cyclical stretch induces structural changes in atrial myocytes. De Jong AM, etal., J Cell Mol Med. 2013 Jun;17(6):743-53. doi: 10.1111/jcmm.12064. Epub 2013 Apr 26.
16. Serum levels of N--terminal proB--type natriuretic peptide in mechanically ventilated critically ill patients -- relation to tidal volume size and development of acute respiratory distress syndrome. Determann RM, etal., BMC Pulm Med. 2013 Jul 9;13(1):42.
17. B-type natriuretic peptide concentrations in contemporary Eisenmenger syndrome patients: predictive value and response to disease targeting therapy. Diller GP, etal., Heart. 2012 May;98(9):736-42. doi: 10.1136/heartjnl-2011-301522. Epub 2012 Mar 7.
18. N-terminal-pro-brain natriuretic peptide, but not brain natriuretic peptide, is increased in patients with severe obesity. Fernandes F, etal., Braz J Med Biol Res. 2007 Feb;40(2):153-8.
19. Prognostic value of NT-proBNP in patients with severe COVID-19. Gao L, etal., Respir Res. 2020 Apr 15;21(1):83. doi: 10.1186/s12931-020-01352-w.
20. NPRA-mediated suppression of AngII-induced ROS production contribute to the antiproliferative effects of B-type natriuretic peptide in VSMC. Gao P, etal., Mol Cell Biochem. 2009 Apr;324(1-2):165-72. Epub 2008 Dec 23.
21. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
22. Long-term effects of B-type natriuretic peptide infusion after acute myocardial infarction in a rat model. George I, etal., J Cardiovasc Pharmacol. 2010 Jan;55(1):14-20.
23. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
24. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. Goetze JP, etal., Eur Heart J. 2006 Dec;27(24):3004-10. Epub 2006 Nov 21.
25. Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo. Grebe C, etal., Cardiovasc Res. 2011 Jun 1;90(3):521-8. doi: 10.1093/cvr/cvr023. Epub 2011 Jan 27.
26. [Effects of buyang huanwu decoction on the sarcoplasmic reticulum calcium uptake in abdominal aortic constriction induced myocardial hypertrophic rats]. Gu YP, etal., Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013 May;33(5):627-31.
27. Parallel gene expressions of IL-6 and BNP during cardiac hypertrophy complicated with diastolic dysfunction in spontaneously hypertensive rats. Haugen E, etal., Int J Cardiol. 2007 Jan 31;115(1):24-8. Epub 2006 Jun 8.
28. Studies on biochemical markers in cryoinfarction in rats. Hemalatha T, etal., Cryo Letters. 2006 Sep-Oct;27(5):311-8.
29. Hyperhomocysteinemia and myocardial expression of brain natriuretic peptide in rats. Herrmann M, etal., Clin Chem. 2007 Apr;53(4):773-80. Epub 2007 Feb 15.
30. B-type natriuretic peptide infusions in acute myocardial infarction. Hillock RJ, etal., Heart. 2008 May;94(5):617-22. Epub 2007 Jul 16.
31. Increased plasma levels and blunted effects of brain natriuretic peptide in rats with congestive heart failure. Hoffman A, etal., Am J Hypertens. 1991 Jul;4(7 Pt 1):597-601.
32. B-Type Natriuretic Peptide Deletion Leads to Progressive Hypertension, Associated Organ Damage, and Reduced Survival: Novel Model for Human Hypertension. Holditch SJ, etal., Hypertension. 2015 Jul;66(1):199-210. doi: 10.1161/HYPERTENSIONAHA.115.05610. Epub 2015 May 11.
33. B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease. Holditch SJ, etal., Kidney Int. 2017 Sep;92(3):657-668. doi: 10.1016/j.kint.2017.02.017. Epub 2017 Apr 14.
34. Effects of brain natriuretic peptide on contraction and intracellular Ca2+ in ventricular myocytes from the streptozotocin-induced diabetic rat. Howarth FC, etal., Ann N Y Acad Sci. 2006 Nov;1084:155-65.
35. Regional cardiac expression and concentration of natriuretic peptides in patients with severe chronic heart failure. Hystad ME, etal., Acta Physiol Scand. 2001 Apr;171(4):395-403.
36. Molecular forms of human brain natriuretic peptide (BNP) in plasma of patients on hemodialysis (HD). Ishizaka Y, etal., Clin Nephrol. 1995 Apr;43(4):237-42.
37. Occurrence of a novel cardiac natriuretic peptide in rats. Itoh H, etal., Biochem Biophys Res Commun. 1989 Jun 15;161(2):732-9. doi: 10.1016/0006-291x(89)92661-2.
38. B-type natriuretic peptide versus amino terminal pro-B type natriuretic peptide: selecting the optimal heart failure marker in patients with impaired kidney function. Jafri L, etal., BMC Nephrol. 2013 May 31;14:117. doi: 10.1186/1471-2369-14-117.
39. B-type natriuretic peptide and risk of contrast-induced acute kidney injury in acute ST-segment-elevation myocardial infarction: a substudy from the HORIZONS-AMI trial. Jarai R, etal., Circ Cardiovasc Interv. 2012 Dec;5(6):813-20. doi: 10.1161/CIRCINTERVENTIONS.112.972356. Epub 2012 Nov 27.
40. A new, fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases. Jensen KT, etal., Scand J Clin Lab Invest. 1997 Oct;57(6):529-40.
41. Isolation and sequence determination of rat cardiac natriuretic peptide. Kambayashi Y, etal., Biochem Biophys Res Commun. 1989 Aug 30;163(1):233-40. doi: 10.1016/0006-291x(89)92126-8.
42. Distinct roles of mitogen-activated protein kinase pathways in GATA-4 transcription factor-mediated regulation of B-type natriuretic peptide gene.PG - 13752-60 Kerkela R, etal., J Biol Chem 2002 Apr 19;277(16):13752-60.
43. Altered regulation of nitric oxide and natriuretic peptide system in cisplatin-induced nephropathy. Kim CS, etal., Regul Pept. 2012 Feb 10;174(1-3):65-70. doi: 10.1016/j.regpep.2011.12.001. Epub 2011 Dec 28.
44. Increased plasma type B natriuretic peptide in the acute phase of Kawasaki disease. Kishimoto S, etal., Pediatr Int. 2011 Oct;53(5):736-41. doi: 10.1111/j.1442-200X.2011.03351.x.
45. M-CAT element mediates mechanical stretch-activated transcription of B-type natriuretic peptide via ERK activation. Koivisto E, etal., Can J Physiol Pharmacol. 2011 Aug;89(8):539-50. Epub 2011 Aug 3.
46. Cloning and sequence analysis of cDNA encoding a precursor for rat brain natriuretic peptide. Kojima M, etal., Biochem Biophys Res Commun 1989 Mar 31;159(3):1420-6.
47. A novel variable number of tandem repeat of the natriuretic peptide precursor B gene's 5'-flanking region is associated with essential hypertension among Japanese females. Kosuge K, etal., Int J Med Sci. 2007 May 16;4(3):146-52.
48. N-terminal pro-Brain Natriuretic Peptide and Risk of Diabetes. Lazo M, etal., Diabetes. 2013 Jun 3.
49. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Leuchte HH, etal., Chest. 2007 Feb;131(2):402-9.
50. Clinical and pathological investigation of severe COVID-19 patients. Li S, etal., JCI Insight. 2020 May 19. pii: 138070. doi: 10.1172/jci.insight.138070.
51. NT Pro BNP Plasma Level and Atrial Volume Are Linked to the Severity of Liver Cirrhosis. Licata A, etal., PLoS One. 2013 Aug 5;8(8):e68364. doi: 10.1371/journal.pone.0068364. Print 2013.
52. [Short- and long-term therapeutic effects of combination therapy with perindopril and irbesartan in a rat model of dilated cardiomyopathy.] Ma GT, etal., Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2007 Aug;32(4):594-8.
53. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. Ma KK, etal., J Mol Cell Cardiol. 2004 Apr;36(4):505-13.
54. Development of cardiac hypertrophy by sunitinib in vivo and in vitro rat cardiomyocytes is influenced by the aryl hydrocarbon receptor signaling pathway. Maayah ZH, etal., Arch Toxicol. 2014 Mar;88(3):725-38. doi: 10.1007/s00204-013-1159-5. Epub 2013 Nov 19.
55. NT-pro brain natriuretic peptide levels and the risk of death in the cooperative study of sickle cell disease. Machado RF, etal., Br J Haematol. 2011 Aug;154(4):512-20. doi: 10.1111/j.1365-2141.2011.08777.x. Epub 2011 Jun 21.
56. Transgenic overexpression of brain natriuretic peptide prevents the progression of diabetic nephropathy in mice. Makino H, etal., Diabetologia. 2006 Oct;49(10):2514-24. Epub 2006 Aug 18.
57. Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection. Martin FL, etal., Am J Physiol Regul Integr Comp Physiol. 2012 Jan 15;302(2):R292-9. doi: 10.1152/ajpregu.00194.2011. Epub 2011 Nov 9.
58. Increased S100B serum levels in dilated cardiomyopathy patients. Mazzini GS, etal., J Card Fail. 2007 Dec;13(10):850-4.
59. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
60. Cardiorenal syndrome in hypertensive rats: microalbuminuria, inflammation and ventricular hypertrophy. Moubarak M, etal., Physiol Res. 2012 Mar 6;61(1):13-24. Epub 2011 Dec 20.
61. Increased human brain natriuretic peptide in congestive heart failure. Mukoyama M, etal., N Engl J Med. 1990 Sep 13;323(11):757-8.
62. NT-proANP and BNP in renovascular and in severe and mild essential hypertension. Mussalo H, etal., Kidney Blood Press Res. 2003;26(1):34-41.
63. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. Nakagawa O, etal., J Clin Invest. 1995 Sep;96(3):1280-7.
64. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
65. Natriuretic peptides for early prediction of acute kidney injury in community-acquired pneumonia. Nowak A, etal., Clin Chim Acta. 2013 Apr 18;419:67-72. doi: 10.1016/j.cca.2013.01.014. Epub 2013 Feb 13.
66. Uncoordinated regulation of atrial natriuretic factor and brain natriuretic peptide in lipopolysaccharide-treated Rats. Ogawa T and de Bold AJ, Biomarkers. 2012 Jan 6.
67. Relationship of brain natriuretic peptide with metabolic syndrome parameters: an observational study. Oztekin S, etal., Anadolu Kardiyol Derg. 2011 Dec;11(8):678-84. doi: 10.5152/akd.2011.188. Epub 2011 Oct 28.
68. Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis. Panizo S, etal., Nephrol Dial Transplant. 2013 Sep 7.
69. Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injury. Piuhola J, etal., Clin Sci (Lond). 2008 Feb;114(4):293-304.
70. SNP rs198389 (T-381 C) polymorphism in the B-type natriuretic peptide gene promoter in patients with atherosclerotic renovascular hypertension. Poreba R, etal., Pol Arch Med Wewn. 2009 Apr;119(4):219-24.
71. Elevated N-terminal pro-brain natriuretic peptide is associated with increased mortality in patients with COVID-19: systematic review and meta-analysis. Pranata R, etal., Postgrad Med J. 2020 May 20. pii: postgradmedj-2020-137884. doi: 10.1136/postgradmedj-2020-137884.
72. B-type natriuretic peptide pretreatment attenuates heart ischemia-reperfusion injury in rats. Ren B, etal., Transplant Proc. 2010 Dec;42(10):4496-8.
73. GOA pipeline RGD automated data pipeline
74. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
75. B-type natriuretic peptides are reliable markers of cardiac strain in CKD pediatric patients. Rinat C, etal., Pediatr Nephrol. 2012 Apr;27(4):617-25. doi: 10.1007/s00467-011-2025-4. Epub 2011 Oct 27.
76. Calcium-calmodulin kinase II is the common factor in calcium-dependent cardiac expression and secretion of A- and B-type natriuretic peptides. Ronkainen JJ, etal., Endocrinology. 2007 Jun;148(6):2815-20. Epub 2007 Mar 1.
77. Organization of the gene for iso-rANP, a rat B-type natriuretic peptide. Roy RN and Flynn TG, Biochem Biophys Res Commun 1990 Aug 31;171(1):416-23.
78. Permeability and contractile responses of collecting lymphatic vessels elicited by atrial and brain natriuretic peptides. Scallan JP, etal., J Physiol. 2013 Oct 15;591(Pt 20):5071-81. doi: 10.1113/jphysiol.2013.260042. Epub 2013 Jul 29.
79. BMP type I receptor ALK2 is required for angiotensin II-induced cardiac hypertrophy. Shahid M, etal., Am J Physiol Heart Circ Physiol. 2016 Apr 15;310(8):H984-94. doi: 10.1152/ajpheart.00879.2015. Epub 2016 Feb 12.
80. Detection of membrane-bound guanylate cyclase activity in rat C6 glioma cells at different growth states following activation by natriuretic peptides. Sorci G, etal., Brain Res. 1995 Jun 12;683(1):51-8.
81. Overexpression of brain natriuretic peptide in mice ameliorates immune-mediated renal injury. Suganami T, etal., J Am Soc Nephrol. 2001 Dec;12(12):2652-63.
82. Posttranscriptional Control of BNP Gene Expression in Angiotensin II-Induced Hypertension. Suo M, etal., Hypertension 2002 Mar 1;39(3):803-8.
83. Localization of 54 rat genes, and definition of new synteny groups conserved in the human and the rat. Szpirer C, etal., Mamm Genome 2000 Sep;11(9):729-35
84. The association of brain natriuretic peptide and insulin resistance in obesity-related hypertension. Tekes S and Cikim AS, J Hum Hypertens. 2007 Jul;21(7):546-50. Epub 2007 Mar 29.
85. Regulation of rat brain natriuretic peptide transcription. A potential role for GATA-related transcription factors in myocardial cell gene expression. Thuerauf DJ, etal., J Biol Chem. 1994 Jul 8;269(27):17772-5.
86. Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy: the CARDIGENE study. Tiret L, etal., J Am Coll Cardiol. 2000 Jan;35(1):29-35.
87. Upregulated neurohumoral factors are associated with left ventricular remodeling and poor prognosis in rats with monocrotaline-induced pulmonary arterial hypertension. Usui S, etal., Circ J. 2006 Sep;70(9):1208-15.
88. Serum cytokine and pro-brain natriuretic peptide (BNP) levels in patients with migraine. Uzar E, etal., Eur Rev Med Pharmacol Sci. 2011 Oct;15(10):1111-6.
89. Forkhead class O transcription factor 3a activation and Sirtuin1 overexpression in the hypertrophied myocardium of the diabetic Goto-Kakizaki rat. Vahtola E, etal., J Hypertens. 2008 Feb;26(2):334-44.
90. The prognostic value of pro-B-Type natriuretic peptide in acute pulmonary embolism. Verschuren F, etal., Thromb Res. 2013 Jun;131(6):e235-9. doi: 10.1016/j.thromres.2013.03.009. Epub 2013 Apr 4.
91. Opposite regulation of brain and C-type natriuretic peptides in the streptozotocin-diabetic cardiopathy. Walther T, etal., J Mol Endocrinol. 2000 Jun;24(3):391-5.
92. [Effects of daunorubicin on the expression of brain natriuretic peptide gene in myocardial cells: an in vitroexperiment with cultured myocardial cells from rats] Wang CJ, etal., Zhonghua Yi Xue Za Zhi. 2007 Apr 24;87(16):1144-6.
93. The role of iNOS-derived NO in the antihypertrophic actions of B-type natriuretic peptide in neonatal rat cardiomyocytes. Wang T, etal., Mol Cell Biochem. 2007 Aug;302(1-2):169-77. Epub 2007 May 9.
94. Hypoxia, via stabilization of hypoxia-inducible factor HIF-1alpha is a direct and sufficient stimulus for brain-type natriuretic peptide induction. Weidemann A, etal., Biochem J. 2007 Sep 7;.
95. N-terminal pro-B-type natriuretic peptide in patients with isolated traumatic brain injury: a prospective cohort study. Wu X, etal., J Trauma. 2011 Oct;71(4):820-5; discussion 825.
96. WY14643 improves left ventricular myocardial mitochondrial and systolic functions in obese rats under chronic persistent hypoxia via the PPARα pathway. Yan J, etal., Life Sci. 2021 Feb 1;266:118888. doi: 10.1016/j.lfs.2020.118888. Epub 2020 Dec 10.
97. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. Yan Y, etal., BMJ Open Diabetes Res Care. 2020 Apr;8(1). pii: 8/1/e001343. doi: 10.1136/bmjdrc-2020-001343.
98. Plasma brain natriuretic peptide levels in normotensive noninsulin-dependent diabetic patients with microalbuminuria. Yano Y, etal., J Clin Endocrinol Metab. 1999 Jul;84(7):2353-6.
99. Increased plasma levels and effects of brain natriuretic peptide in experimental nephrosis. Yokota N, etal., Nephron. 1993;65(3):454-9.
100. B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary intervention. Zhang J, etal., Acta Radiol. 2010 Jul;51(6):641-8. doi: 10.3109/02841851.2010.486804.
101. Diagnostic value of serum brain natriuretic peptide in syncope in children and adolescents. Zhang Q, etal., Acta Paediatr. 2013 May;102(5):e210-4. doi: 10.1111/apa.12182. Epub 2013 Feb 21.
102. Growth/differentiation factor 1 alleviates pressure overload-induced cardiac hypertrophy and dysfunction. Zhang Y, etal., Biochim Biophys Acta. 2014 Feb;1842(2):232-44. doi: 10.1016/j.bbadis.2013.11.018. Epub 2013 Nov 23.
103. The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: A single-centre, retrospective, observational study in Wuhan. Zhang Y, etal., Diabetes Obes Metab. 2020 May 14. doi: 10.1111/dom.14086.
104. Inhibition of CYP1B1 ameliorates cardiac hypertrophy induced by uremic toxin. Zhang Y, etal., Mol Med Rep. 2020 Jan;21(1):393-404. doi: 10.3892/mmr.2019.10810. Epub 2019 Nov 11.
105. Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu. Zheng Y, etal., J Clin Virol. 2020 Jun;127:104366. doi: 10.1016/j.jcv.2020.104366. Epub 2020 Apr 10.
106. Brain natriuretic peptide is related to carotid plaques and predicts atherosclerosis in pre-dialysis patients with chronic kidney disease. Zhou W, etal., Eur J Intern Med. 2012 Sep;23(6):539-44. doi: 10.1016/j.ejim.2012.06.001. Epub 2012 Jun 24.
Additional References at PubMed
PMID:1652217   PMID:1660465   PMID:1672777   PMID:2525380   PMID:2673236   PMID:11410403   PMID:12562779   PMID:12727915   PMID:12941780   PMID:15837527   PMID:15911064   PMID:16357805  
PMID:16870210   PMID:17345093   PMID:17566658   PMID:17587490   PMID:17906112   PMID:18006556   PMID:18032399   PMID:18404982   PMID:18408131   PMID:18420944   PMID:18499087   PMID:19139378  
PMID:19721230   PMID:19752486   PMID:20108079   PMID:20559433   PMID:21951964   PMID:22474982   PMID:22547442   PMID:23382219   PMID:23454171   PMID:23497124   PMID:24137001   PMID:24289757  
PMID:24477916   PMID:25063069   PMID:25218476   PMID:25278510   PMID:25669688   PMID:25698234   PMID:25865156   PMID:26136529   PMID:26254181   PMID:26261563   PMID:26838190   PMID:27162120  
PMID:27228659   PMID:27443845   PMID:30221729   PMID:31766450   PMID:33970224   PMID:34359915   PMID:35776316   PMID:36307995  


Genomics

Comparative Map Data
Nppb
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr85163,699,955 - 163,701,314 (+)NCBIGRCr8GRCr8GRCr8
GRCr8 Ensembl5163,699,839 - 163,701,310 (+)EnsemblGRCr8
mRatBN7.25158,416,813 - 158,418,175 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl5158,416,866 - 158,418,168 (+)EnsemblmRatBN7.2
UTH_Rnor_SHR_Utx5161,133,613 - 161,134,915 (+)NCBIUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.05162,961,436 - 162,962,738 (+)NCBIUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.05162,917,783 - 162,919,085 (+)NCBIUTH_Rnor_WKY_Bbb_1.0
Dahl_SR_JrHsd5163,279,648 - 163,280,950 (+)NCBI
Lyon_Normotensive5165,292,669 - 165,293,971 (+)NCBI
Lyon_Hypertensive5164,468,266 - 164,469,568 (+)NCBI
F344_StmMcwi5158,012,664 - 158,013,966 (+)NCBI
Rnor_6.05164,796,176 - 164,797,538 (+)NCBIRnor_6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl5164,796,185 - 164,797,531 (+)EnsemblRnor_6.0 Ensemblrn6Rnor6.0
Rnor_5.05168,454,278 - 168,455,640 (+)NCBIRnor_5.0Rnor_5.0rn5
RGSC_v3.45165,062,348 - 165,063,650 (+)NCBIRGSC_v3.4RGSC_v3.4rn4
Celera5156,698,873 - 156,700,175 (+)NCBICelera
RGSC_v3.15165,072,535 - 165,073,838 (+)NCBI
Cytogenetic Map5q36NCBI
NPPB
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh38111,857,464 - 11,858,945 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl111,857,454 - 11,859,648 (-)EnsemblGRCh38.p14 Ensemblhg38GRCh38
GRCh37111,917,521 - 11,919,002 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 36111,840,108 - 11,841,579 (-)NCBIBuild 36Build 36hg18NCBI36
Build 34111,851,789 - 11,853,254NCBI
Celera111,031,156 - 11,032,627 (-)NCBICelera
Cytogenetic Map1p36.22NCBI
HuRef111,073,021 - 11,074,492 (-)NCBIHuRef
CHM1_1111,905,417 - 11,906,888 (-)NCBICHM1_1
T2T-CHM13v2.0111,401,560 - 11,403,041 (-)NCBIT2T-CHM13v2.0
Nppb
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm394148,070,264 - 148,071,662 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl4148,069,859 - 148,071,662 (+)EnsemblGRCm39 EnsemblGRCm39
GRCm384147,985,786 - 147,987,205 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl4147,985,788 - 147,987,205 (+)EnsemblGRCm38.p6 Ensemblmm10GRCm38
MGSCv374147,359,898 - 147,361,314 (+)NCBIMGSCv37MGSCv37mm9NCBIm37
MGSCv364146,829,697 - 146,830,998 (+)NCBIMGSCv36mm8
Celera4150,250,201 - 150,251,617 (+)NCBICelera
Cytogenetic Map4E1NCBI
cM Map478.57NCBI
Nppb
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0NW_0049554862,054,775 - 2,056,130 (+)NCBIChiLan1.0ChiLan1.0
NPPB
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
NHGRI_mPanPan1-v21216,361,604 - 216,364,862 (+)NCBINHGRI_mPanPan1-v2
NHGRI_mPanPan11215,008,742 - 215,011,988 (+)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v0110,621,416 - 10,622,960 (-)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.1111,838,518 - 11,839,999 (-)NCBIPanPan1.1PanPan1.1panPan2
PanPan1.1 Ensembl111,838,518 - 11,839,995 (-)EnsemblPanPan1.1 EnsemblpanPan2panpan1.1
NPPB
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.1284,395,844 - 84,397,473 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha280,929,289 - 80,930,932 (+)NCBIDog10K_Boxer_TashaDog10K_Boxer_Tasha
ROS_Cfam_1.0285,060,368 - 85,062,010 (+)NCBIROS_Cfam_1.0ROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl285,060,271 - 85,073,309 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.1281,809,597 - 81,811,239 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.0282,809,514 - 82,811,156 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.0283,872,280 - 83,873,924 (+)NCBIUU_Cfam_GSD_1.0UU_Cfam_GSD_1.0
Nppb
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mIctTri1.hap1117,647,644 - 7,651,313 (-)NCBImIctTri1.hap1
HiC_Itri_2NW_02440505834,858,528 - 34,860,962 (-)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_004936474683,325 - 684,665 (-)EnsemblSpeTri2.0 Ensembl
SpeTri2.0NW_004936474683,325 - 684,662 (-)NCBISpeTri2.0SpeTri2.0SpeTri2.0
NPPB
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl671,930,382 - 71,932,254 (-)EnsemblSscrofa11.1 EnsemblsusScr11Sscrofa11.1
Sscrofa11.1671,930,374 - 71,931,843 (-)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.2665,840,061 - 65,841,530 (-)NCBISscrofa10.2Sscrofa10.2susScr3
NPPB
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mChlSab1.0.hap120124,958,571 - 124,960,059 (+)NCBImChlSab1.0.hap1
Vero_WHO_p1.0NW_02366605423,799,168 - 23,801,437 (+)NCBIVero_WHO_p1.0Vero_WHO_p1.0
ChlSab1.120119,930,931 - 119,933,391 (+)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl20119,932,021 - 119,933,197 (+)EnsemblChlSab1.1 EnsemblchlSab2Vervet-AGM
Nppb
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla 1.0NW_0046248181,139,776 - 1,141,010 (+)NCBIHetGla 1.0HetGla 1.0hetGla2
Nppb
(Rattus rattus - black rat)
Black Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Rrattus_CSIRO_v1112,786,337 - 12,787,710 (-)NCBIRrattus_CSIRO_v1Rrattus_CSIRO_v1

Variants

.
Variants in Nppb
6 total Variants
miRNA Target Status (No longer updated)

Predicted Target Of
Summary Value
Count of predictions:221
Count of miRNA genes:132
Interacting mature miRNAs:142
Transcripts:ENSRNOT00000010779
Prediction methods:Microtar, Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (GRCr8)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
10053720Scort26Serum corticosterone level QTL 262.060.0147blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)5130249266172190305Rat
1354583Despr3Despair related QTL34.980.0002locomotor behavior trait (VT:0001392)amount of time spent in voluntary immobility (CMO:0001043)5132930505172190305Rat
631498Bp100Blood pressure QTL 1004.90.001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)5163701314163712184Rat
61444Strs2Sensitivity to stroke QTL 24.7cerebrum integrity trait (VT:0010549)post-insult time to onset of cerebrovascular lesion (CMO:0002343)5141212838172190305Rat
1300119Bp180Blood pressure QTL 1803.82arterial blood pressure trait (VT:2000000)blood pressure time series experimental set point of the baroreceptor response (CMO:0002593)5149642129171146538Rat
1549904Neuinf1Neuroinflammation QTL 130nervous system integrity trait (VT:0010566)blood T lymphocyte count (CMO:0000110)5160111176171146538Rat
61452Ciaa5CIA Autoantibody QTL 53.5blood autoantibody amount (VT:0003725)calculated serum anti-rat type 2 collagen autoantibody titer (CMO:0001281)599905133172190305Rat
8552908Pigfal4Plasma insulin-like growth factor 1 level QTL 46.6blood insulin-like growth factor amount (VT:0010479)plasma insulin-like growth factor 1 level (CMO:0001299)5133789363172190305Rat
1331803Rf32Renal function QTL 322.798kidney blood vessel physiology trait (VT:0100012)absolute change in renal vascular resistance (CMO:0001900)5134369199172190305Rat
61393Bp7Blood pressure QTL 74.50.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)565089051166764498Rat
7794791Mcs33Mammary carcinoma susceptibility QTL 331.93mammary gland integrity trait (VT:0010552)mammary tumor incidence/prevalence measurement (CMO:0000946)5136631198172190305Rat
1354631Swd2Spike wave discharge measurement QTL 23.640.0002brain electrophysiology trait (VT:0010557)brain total spike-and-wave discharge duration (CMO:0001740)5156396728172190305Rat
1598861Cm64Cardiac mass QTL 642.9heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)5133081618172190305Rat
1578766Tcas11Tongue tumor susceptibility QTL 114.12tongue integrity trait (VT:0010553)number of squamous cell tumors of the tongue with diameter greater than 3 mm (CMO:0001950)551657967166600247Rat
631505Bp103Blood pressure QTL 1033.2arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)5138002522170842766Rat
1581505Rf54Renal function QTL 54kidney physiology trait (VT:0002136)kidney 20-HETE level (CMO:0001854)5133270647172190305Rat
1641920Colcs1Colorectal carcinoma susceptibility QTL 12.990.0055intestine integrity trait (VT:0010554)benign colorectal tumor surface area measurement (CMO:0001799)5160071170172129029Rat
2317753Glom24Glomerulus QTL 243.1kidney glomerulus integrity trait (VT:0010546)kidney sclerotic glomeruli count to total glomeruli count ratio (CMO:0001269)5141764300172190305Rat
8694169Bw148Body weight QTL 14850.001body mass (VT:0001259)body weight gain (CMO:0000420)5133789363172190305Rat
1331721Bp210Blood pressure QTL 2103.413arterial blood pressure trait (VT:2000000)blood pressure time series experimental set point of the baroreceptor response (CMO:0002593)5148093485172129029Rat
1581510Cm54Cardiac mass QTL 543.40.05heart left ventricle mass (VT:0007031)heart left ventricle weight to body weight ratio (CMO:0000530)5125969677172190305Rat
1576312Emca8Estrogen-induced mammary cancer QTL 84.1mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)555124766172190305Rat
631272Lanf1Left ventricular atrial natriuretic factor QTL 112heart left ventricle natriuretic peptide A amount (VT:0010596)heart left ventricle natriuretic peptide A level (CMO:0002165)5156396728167181764Rat
724525Bp147Blood pressure QTL 1474.30.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)5131708216172190305Rat
2313096Bmd78Bone mineral density QTL 783.10.0001tibia mineral mass (VT:1000283)total volumetric bone mineral density (CMO:0001728)5149661912166600247Rat
1298090Bp155Blood pressure QTL 1553.8arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)5156289283171137955Rat
1598819Bp292Blood pressure QTL 2924.3arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)5133081618172190305Rat

Markers in Region
D5Wox33  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.25158,414,892 - 158,415,237 (+)MAPPERmRatBN7.2
Rnor_6.05164,794,256 - 164,794,600NCBIRnor6.0
Rnor_5.05168,452,358 - 168,452,702UniSTSRnor5.0
RGSC_v3.45165,060,375 - 165,060,719UniSTSRGSC3.4
Celera5156,696,900 - 156,697,244UniSTS
Cytogenetic Map5q36UniSTS
RH130424  
Rat AssemblyChrPosition (strand)SourceJBrowse
GRCr85163,700,508 - 163,701,146 (+)Marker Load Pipeline
mRatBN7.25158,417,366 - 158,418,004 (+)MAPPERmRatBN7.2
Rnor_6.05164,796,730 - 164,797,367NCBIRnor6.0
Rnor_5.05168,454,832 - 168,455,469UniSTSRnor5.0
RGSC_v3.45165,062,849 - 165,063,486UniSTSRGSC3.4
Celera5156,699,374 - 156,700,011UniSTS
RH 3.4 Map51105.8UniSTS
Cytogenetic Map5q36UniSTS


Related Rat Strains
The following Strains have been annotated to Nppb
SD    


Genetic Models
This gene Nppb is modified in the following models/strains:
SS-Nppbem4Mcwi     SS-Nppbem2Mcwi-/-     SS-Nppbem2Mcwi    


Expression

RNA-SEQ Expression

adipose tissue
alimentary part of gastrointestinal system
appendage
circulatory system
ectoderm
endocrine system
endoderm
entire extraembryonic component
exocrine system
hemolymphoid system
hepatobiliary system
integumental system
mesenchyme
mesoderm
musculoskeletal system
nervous system
pharyngeal arch
renal system
reproductive system
respiratory system
sensory system
visual system
61 27 100 1360 552 125 252 133 72 77 60 88 1991 1668 108 497 20 182 285 213 15 15

Sequence


Ensembl Acc Id: ENSRNOT00000010779   ⟹   ENSRNOP00000010778
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr8 Ensembl5163,699,839 - 163,701,310 (+)Ensembl
mRatBN7.2 Ensembl5158,416,866 - 158,418,168 (+)Ensembl
Rnor_6.0 Ensembl5164,796,185 - 164,797,531 (+)Ensembl
Ensembl Acc Id: ENSRNOT00000103871   ⟹   ENSRNOP00000088183
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr8 Ensembl5163,700,008 - 163,700,880 (+)Ensembl
mRatBN7.2 Ensembl5158,416,866 - 158,417,901 (+)Ensembl
RefSeq Acc Id: NM_031545   ⟹   NP_113733
RefSeq Status: PROVISIONAL
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr85163,700,008 - 163,701,310 (+)NCBI
mRatBN7.25158,416,866 - 158,418,168 (+)NCBI
Dahl_SR_JrHsd5163,279,648 - 163,280,950 (+)NCBI
Lyon_Normotensive5165,292,669 - 165,293,971 (+)NCBI
Lyon_Hypertensive5164,468,266 - 164,469,568 (+)NCBI
F344_StmMcwi5158,012,664 - 158,013,966 (+)NCBI
Rnor_6.05164,796,229 - 164,797,531 (+)NCBI
Rnor_5.05168,454,278 - 168,455,640 (+)NCBI
RGSC_v3.45165,062,348 - 165,063,650 (+)RGD
Celera5156,698,873 - 156,700,175 (+)RGD
Sequence:
RefSeq Acc Id: XM_006239376   ⟹   XP_006239438
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr85163,699,955 - 163,701,314 (+)NCBI
mRatBN7.25158,416,813 - 158,418,175 (+)NCBI
Rnor_6.05164,796,176 - 164,797,538 (+)NCBI
Rnor_5.05168,454,278 - 168,455,640 (+)NCBI
Sequence:
RefSeq Acc Id: NP_113733   ⟸   NM_031545
- Peptide Label: precursor
- UniProtKB: P13205 (UniProtKB/Swiss-Prot)
- Sequence:
RefSeq Acc Id: XP_006239438   ⟸   XM_006239376
- Peptide Label: isoform X1
- UniProtKB: A0ACJ1L6M8 (UniProtKB/TrEMBL)
- Sequence:
Ensembl Acc Id: ENSRNOP00000010778   ⟸   ENSRNOT00000010779
Ensembl Acc Id: ENSRNOP00000088183   ⟸   ENSRNOT00000103871

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P13205-F1-model_v2 AlphaFold P13205 1-121 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:13694253
Promoter ID:EPDNEW_R4778
Type:single initiation site
Name:Nppb_1
Description:natriuretic peptide B
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.05164,796,205 - 164,796,265EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:3194 AgrOrtholog
BioCyc Gene G2FUF-39202 BioCyc
Ensembl Genes ENSRNOG00000008141 Ensembl, ENTREZGENE
  ENSRNOG00055022304 UniProtKB/Swiss-Prot
  ENSRNOG00060026636 UniProtKB/Swiss-Prot
  ENSRNOG00065011536 UniProtKB/Swiss-Prot
Ensembl Transcript ENSRNOT00000010779 ENTREZGENE
  ENSRNOT00055038329 UniProtKB/Swiss-Prot
  ENSRNOT00060046140 UniProtKB/Swiss-Prot
  ENSRNOT00065018755 UniProtKB/Swiss-Prot
InterPro Natr_peptide UniProtKB/Swiss-Prot
  Natr_peptide_CS UniProtKB/Swiss-Prot
  Natriuretic_peptide UniProtKB/Swiss-Prot
  Natriuretic_peptide_brain UniProtKB/Swiss-Prot
KEGG Report rno:25105 UniProtKB/Swiss-Prot
NCBI Gene 25105 ENTREZGENE
PANTHER ATRIAL NATRIURETIC FACTOR PRECURSOR UniProtKB/Swiss-Prot
  NATRIURETIC PEPTIDES B UniProtKB/Swiss-Prot
Pfam ANP UniProtKB/Swiss-Prot
PharmGKB NPPB RGD
PhenoGen Nppb PhenoGen
PRINTS BNATPEPTIDE UniProtKB/Swiss-Prot
PROSITE NATRIURETIC_PEPTIDE UniProtKB/Swiss-Prot
RatGTEx ENSRNOG00000008141 RatGTEx
  ENSRNOG00055022304 RatGTEx
  ENSRNOG00060026636 RatGTEx
  ENSRNOG00065011536 RatGTEx
SMART NAT_PEP UniProtKB/Swiss-Prot
UniProt A0A8I6AIA6_RAT UniProtKB/TrEMBL
  A0ACJ1L6M8 ENTREZGENE, UniProtKB/TrEMBL
  ANFB_RAT UniProtKB/Swiss-Prot, ENTREZGENE


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2011-08-02 Nppb  natriuretic peptide B  Nppb  natriuretic peptide precursor B  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2008-10-10 Nppb  natriuretic peptide precursor B  Nppb  natriuretic peptide precursor type B  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2001-10-23 Nppb  natriuretic peptide precursor type B      Name updated to reflect Human and Mouse nomenclature 68913 APPROVED

RGD Curation Notes
Note Type Note Reference
gene_cellular_localization secreted by cardiac myocytes 728927
gene_disease upregulated in congestive heart failure and hypertension 70484
gene_disease expression increased in patients with heart failure 70484
gene_expression expressed in myocardial cells 70484
gene_process regulates blood pressure and fluid homeostasis 61490
gene_process regulates blood pressure and fluid homeostasis 70484